Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

Share this page:

Title

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report

Subject

Description

The mRNA-1273 vaccine against SARS-CoV-2 elicited high neutralizing-antibody titers in phase 1 trial participants and has been shown to be highly efficacious in preventing symptomatic Covid-19 disease and severe disease.

Date Last Updated (Year-Month-Day)

2021-02-17

Citation

Wu, Kai, Anne P. Werner, Matthew Koch, Angela Choi, Elisabeth Narayanan, Guillaume B. E. Stewart-Jones, Tonya Colpitts, Hamilton Bennett, Seyhan Boyoglu-Barnum, Wei Shi, Juan I. Moliva, Nancy J. Sullivan, Barney S. Graham, Andrea Carfi, Kizzmekia S. Corbett, Robert A. Seder, and Darin K. Edwards. 2021. "Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine — Preliminary Report." New England Journal of Medicine.

Accessibility

Free online on NEJM.